AVR's Principal Activity is the the manufacturing and sale of proprietary ADAPT regenerative tissue products globally and continued research and development of regenerative medicine. Products under development in the aortic valve repair and replacement programme include DurAVRTM.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+133.25%|
|vs ASX 200 (1yr)||+119.77%|
|ASX Rank||1,210 of 2,295|
|Sector Rank||101 of 177|
Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.
Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Stephen (Steve) Denaro||Company Secretary,Non-Executive Director||Oct 2018||
Mr Stephen (Steve) Denaro
Company Secretary,Non-Executive Director
Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.
|Dr Wenyi Gu||Non-Executive Director||Oct 2018||
Dr Wenyi Gu
Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.
|Mr Wayne Paterson||Managing Director,Chief Executive Officer||Feb 2016||
Mr Wayne Paterson
Managing Director,Chief Executive Officer
Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.
|Mr John Seaberg||Non-Executive Director,Non-Executive Chairman||Oct 2014||
Mr John Seaberg
Non-Executive Director,Non-Executive Chairman
Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.
|Matthew Mcdonnell||Chief Financial Officer||N/A|
|David St Denis||Chief Operating Officer||N/A|
|Martha Engel||General Counsel||N/A|
AVR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|07/06/21||Stephen (Steve) Denaro||Buy||+5,000||$8.009||$40,047||On-market trade|
|10/12/20||Wayne Paterson||Expiry||1,000||$3.80||$3,800||Options expired|
|10/12/20||John Seaberg||Expiry||1,000||$3.80||$3,800||Options expired|
|20/03/20||Stephen (Steve) Denaro||Issued||25,000||$3.50||$87,500||Issue of options|
|20/03/20||Wayne Paterson||Issued||350,000||$3.50||$1,225,000||Issue of options|
|20/03/20||John Seaberg||Issued||60,000||$3.50||$210,000||Issue of options|
|18/12/18||John Seaberg||Issued||700,000||$0.08||$56,000||Rights issue|
|18/12/18||Yanheng Wu||Issued||47,178,461||$0.08||$3,774,278||Rights issue|
|18/12/18||Lishan Zhang||Issued||62,897,248||$0.061||$3,836,732||Rights issue|
|18/12/18||Yanheng Wu||Issued||47,178,461||$0.061||$2,877,886||Rights issue|
|18/12/18||Lishan Zhang||Issued||62,897,248||$0.08||$5,031,781||Rights issue|
The current holdings of AVR directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Stephen (Steve) Denaro||07/06/2021||0||5,000||25,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Sio Partners LP||31/03/2021||1,311,079||19.96|
|Mercer Street Global Opportunity Fund, LLC||31/05/2021||383,367||5.52|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|31-05-21||Mercer Street Global Opportunity Fund, LLC||383,367||--||5.52|
|20-01-21||Mercer Street Global Opportunity Fund LLC||341,545||--||5.20|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|20-05-21||Mercer Street Global Opportunity Fund LLC||335,383||5.06||--|
|13-04-21||Mercer Street Global Opportunity Fund LLC||6,162||5.20||5.06|
|20-01-21||Sio Partners LP||129,809,772||22.20||19.96|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.